Cited 75 times in
Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 라선영 | - |
dc.date.accessioned | 2016-02-04T11:58:42Z | - |
dc.date.available | 2016-02-04T11:58:42Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1558-7673 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/141620 | - |
dc.description.abstract | BACKGROUND: Sarcomatoid renal cell carcinoma is associated with poor prognosis. Data regarding outcome in the targeted therapy era are lacking. PATIENTS AND METHODS: Clinical, prognostic, and treatment parameters in metastatic renal cell carcinoma patients with and without sarcomatoid histology treated with targeted therapy were retrospectively analyzed. RESULTS: Two thousand two hundred eighty-six patients were identified (sRCC: n = 230 and non-sRCC: n = 2056). sRCC patients had significantly worse IMDC prognostic criteria compared with non-sRCC (11% vs. 19% favorable risk; 49% vs. 57% intermediate risk, and 40% vs. 24% poor risk; P < .0001). Time from original diagnosis to relapse (excluding synchronous metastatic disease) was shorter in the sRCC group (18.8 vs. 42.9 months; P < .0001). There was no significant difference in the incidence of central nervous system metastases (6%-8%) or underlying clear cell histology (87%-88%). More than 93% of patients received VEGF inhibitors as first-line therapy; objective response was less common in sRCC whereas primary refractory disease was more common (21% vs. 26% and 43% vs. 21%; P < .0001, for both). sRCC patients had significantly less use of second- (P = .018) and third-line (P < .0001) systemic therapy. The median progression-free survival (PFS)/overall survival (OS) was 4.5/10.4 months in sRCC patients and 7.8/22.5 months in non-sRCC patients (P < .0001 for both). Sarcomatoid histology was associated with a significantly worse PFS and OS after adjusting for individual IMDC risk factors in multivariable analysis (hazard ratio, 1.5; P < .0001 for both). CONCLUSION: Patients with sRCC have a shorter time to relapse, worse baseline prognostic criteria, and worse clinical outcome with targeted therapy. Additional insight into the biology of sRCC is needed to develop alternative therapeutics. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | e79~e85 | - |
dc.relation.isPartOf | CLINICAL GENITOURINARY CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Angiogenesis Inhibitors/therapeutic use* | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Carcinoma, Renal Cell/drug therapy* | - |
dc.subject.MESH | Carcinoma, Renal Cell/pathology | - |
dc.subject.MESH | Databases, Factual | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kidney Neoplasms/drug therapy* | - |
dc.subject.MESH | Kidney Neoplasms/pathology | - |
dc.subject.MESH | Molecular Targeted Therapy | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Neoplasm Recurrence, Local/pathology* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Vascular Endothelial Growth Factor A/antagonists & inhibitors | - |
dc.title | Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Christos E. Kyriakopoulos | - |
dc.contributor.googleauthor | Namita Chittoria | - |
dc.contributor.googleauthor | Toni K. Choueiri | - |
dc.contributor.googleauthor | Nils Kroeger | - |
dc.contributor.googleauthor | Jae-Lyun Lee | - |
dc.contributor.googleauthor | Sandy Srinivas | - |
dc.contributor.googleauthor | Jennifer J. Knox | - |
dc.contributor.googleauthor | Georg A. Bjarnason | - |
dc.contributor.googleauthor | Scott D. Ernst | - |
dc.contributor.googleauthor | Lori A. Wood | - |
dc.contributor.googleauthor | Ulka N. Vaishampayan | - |
dc.contributor.googleauthor | Neeraj Agarwal | - |
dc.contributor.googleauthor | Sumanta K. Pal | - |
dc.contributor.googleauthor | Ravindran Kanesvaran | - |
dc.contributor.googleauthor | Sun-Young Rha | - |
dc.contributor.googleauthor | Takeshi Yuasa | - |
dc.contributor.googleauthor | Frede Donskov | - |
dc.contributor.googleauthor | Scott A. North | - |
dc.contributor.googleauthor | Daniel Y. Heng | - |
dc.contributor.googleauthor | Brian I. Rini | - |
dc.identifier.doi | 10.1016/j.clgc.2014.08.011 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J00575 | - |
dc.identifier.eissn | 1938-0682 | - |
dc.identifier.pmid | 25450036 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S1558767314002043 | - |
dc.subject.keyword | IMDC risk model | - |
dc.subject.keyword | Kidney cancer | - |
dc.subject.keyword | Overall survival | - |
dc.subject.keyword | Prognostication | - |
dc.subject.keyword | Targeted therapies | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 13 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 79 | - |
dc.citation.endPage | 85 | - |
dc.identifier.bibliographicCitation | CLINICAL GENITOURINARY CANCER, Vol.13(2) : 79-85, 2015 | - |
dc.identifier.rimsid | 30770 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.